Growth Metrics

Eli Lilly (LLY) Total Non-Current Liabilities (2016 - 2025)

Eli Lilly (LLY) has disclosed Total Non-Current Liabilities for 17 consecutive years, with $80.1 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Non-Current Liabilities rose 121.99% year-over-year to $80.1 billion, compared with a TTM value of $80.1 billion through Dec 2025, up 121.99%, and an annual FY2025 reading of $80.1 billion, up 121.99% over the prior year.
  • Total Non-Current Liabilities was $80.1 billion for Q4 2025 at Eli Lilly, up from $50.9 billion in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $80.1 billion in Q4 2025 and bottomed at $21.6 billion in Q4 2022.
  • Average Total Non-Current Liabilities over 5 years is $32.5 billion, with a median of $26.3 billion recorded in 2021.
  • The sharpest move saw Total Non-Current Liabilities decreased 18.49% in 2022, then soared 121.99% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $24.6 billion in 2021, then decreased by 12.29% to $21.6 billion in 2022, then grew by 19.81% to $25.8 billion in 2023, then soared by 39.53% to $36.1 billion in 2024, then skyrocketed by 121.99% to $80.1 billion in 2025.
  • Business Quant data shows Total Non-Current Liabilities for LLY at $80.1 billion in Q4 2025, $50.9 billion in Q3 2025, and $43.6 billion in Q2 2025.